Peter-Brian Andersson, MD
Neurology · Tarzana, CANPI 1326063843
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $69,700 of the $97,440 with a category attached, or 71.5%. 60 manufacturers reported payments, led by AbbVie at 38.2% of the total. Reporting peaked in 2022 at $24,236 and has fallen 59.8% since, to $9,734 in 2025. Among neurology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,193 payments — averaging $81.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$37K
- Lilly USA, LLC$25K
- Biohaven Pharmaceuticals, Inc.$12K
- Impel Pharmaceuticals Inc.$4K
- Teva Pharmaceuticals USA, Inc.$1K
- Biogen$1K
- plus $16K from 54 others
What the payments were for
- Consulting fees$3,9764%
- Speaking & faculty fees$69,70072%
- Grants$850%
- Travel & lodging$1910%
- Food & beverage$23,17424%
- Education$3140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$97,440 in reported general payments places this provider in the 90th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Radicava OrsEdaravone | 16 | $227,788 |
| NuplazidPimavanserin Tartrate | 35 | $174,678 |
| GocovriAmantadine Hcl | 48 | $161,957 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 16 | $131,923 |
| Nurtec OdtRimegepant Sulfate | 66 | $87,273 |
| Aimovig AutoinjectorErenumab-Aooe | 87 | $67,879 |
| BriviactBrivaracetam | 22 | $49,861 |
| FycompaPerampanel | 25 | $35,397 |
| QuliptaAtogepant | 25 | $26,647 |
| Emgality PenGalcanezumab-Gnlm | 31 | $26,319 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 28 | $23,416 |
| OngentysOpicapone | 23 | $15,483 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 223 | $9,806 |
| TrintellixVortioxetine Hydrobromide | 13 | $6,273 |
| Pregabalin | 133 | $5,599 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $825 | $174,67835 claims |
| MDD US Operations, LLCGocovri | $769 | $161,95748 claims |
| PfizerNurtec Odt, Dilantin | $788 | $89,14177 claims |
| UCB, Inc.Briviact | $510 | $49,86122 claims |
| Eisai Inc.Fycompa | $702 | $35,39725 claims |
| AbbVieQulipta | $37,270 | $26,64725 claims |
| Neurocrine Biosciences, Inc.Ongentys | $589 | $15,48323 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $263 | $6,27313 claims |
| Amneal Pharmaceuticals LLCMycophenolate Mofetil | $348 | $96021 claims |
| Upsher-smith Laboratories LLCTopiramate | $99 | $48122 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,996 neurology providers in California.
Other neurology in Tarzana
- Andrew BlumenfeldCarlsbad$4.9M
- Khashayar DashtipourLoma Linda$3.3M
- Regina BerkovichWest Hollywood$3M
- Daniel BandariNewport Beach$2.6M
- Perry ShiehLos Angeles$2.4M
- Sandeep ThakkarIrvine$2M
- David LiebeskindLos Angeles$1.9M
- Jack SchimCarlsbad$1.7M
- Parshaw DorrizMission Viejo$1.5M
- Benjamin FrishbergCarlsbad$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.